Sam Brusco, Associate Editor02.03.23
LivaNova has launched SenTiva DUO, an implantable pulse generator (IPG) with a dual-pin header to provide the company’s proprietary VNS Therapy to treat drug-resistant epilepsy.
The dual-pin header differs from the original SenTiva, which has a single-pin format. Patients originally implanted with a dual-pin lead and IPG can now receive the benefits of the firm’s latest VNS Therapy tech.
“This new offering enables those VNS Therapy patients with legacy dual-pin systems to have the option to replace their device with SenTiva DUO, delivering the most advanced VNS Therapy treatment without the need for lead revision,” Dr. James Wheless, Professor and Chief, Pediatric Neurology, Le Bonheur Children’s Hospital told the press. “Having access to SenTiva DUO offers patients therapy that can be customized and delivered automatically, providing optimal seizure control and enabling maximum adherence to treatment.”
SenTiva DUO offers stimulation in response to rapid heart rate increases, which can be associated with seizures. It also allows day-night programming, scheduled programming, and logs low heart rate and prone position events.
“We’re proud to offer SenTiva DUO to serve patients who were early adopters of VNS Therapy many years ago,” said Damien McDonald, CEO of LivaNova. “Over time, all VNS Therapy patients must replace their generators as batteries become depleted. Now, our ‘pioneer patients’ will be able to take advantage of the latest technology with SenTiva DUO and experience the full benefits of VNS Therapy, without the need to replace their dual-pin lead.”
The dual-pin header differs from the original SenTiva, which has a single-pin format. Patients originally implanted with a dual-pin lead and IPG can now receive the benefits of the firm’s latest VNS Therapy tech.
“This new offering enables those VNS Therapy patients with legacy dual-pin systems to have the option to replace their device with SenTiva DUO, delivering the most advanced VNS Therapy treatment without the need for lead revision,” Dr. James Wheless, Professor and Chief, Pediatric Neurology, Le Bonheur Children’s Hospital told the press. “Having access to SenTiva DUO offers patients therapy that can be customized and delivered automatically, providing optimal seizure control and enabling maximum adherence to treatment.”
SenTiva DUO offers stimulation in response to rapid heart rate increases, which can be associated with seizures. It also allows day-night programming, scheduled programming, and logs low heart rate and prone position events.
“We’re proud to offer SenTiva DUO to serve patients who were early adopters of VNS Therapy many years ago,” said Damien McDonald, CEO of LivaNova. “Over time, all VNS Therapy patients must replace their generators as batteries become depleted. Now, our ‘pioneer patients’ will be able to take advantage of the latest technology with SenTiva DUO and experience the full benefits of VNS Therapy, without the need to replace their dual-pin lead.”